Navigation Links
Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
Date:4/18/2008

SMYRNA, Ga., April 18 /PRNewswire/ -- Data presented today at a platform session of the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago support the potential for adjunctive use of intravenous lacosamide 200-600 mg/day using infusion durations as fast as 10 minutes for short term replacement of oral lacosamide in adult patients with partial onset seizures.

Regulatory filings for lacosamide oral tablet, oral syrup and intravenous formulation are currently under review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for use as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.

"When patients are temporarily hospitalized or undergo surgical procedures making it difficult to swallow, they may not be able to take their oral antiepileptic drug. In these circumstances, and in order to maintain seizure control, a short-term, alternative administration of their antiepileptic medication is desirable," said Gregory Krauss, MD, Department of Neurology, Johns Hopkins Epilepsy Center, Baltimore. "In this study, short-term intravenous therapy with lacosamide was well tolerated when substituted for oral lacosamide treatment in patients with certain epilepsy types."

The study was a multi-center, multi-national, open-label trial of 160 patients who were receiving oral lacosamide for at least eight weeks. For the last two weeks of the trial, these patients were on a stable twice daily dosing regimen of lacosamide (200-800 mg/day), as well as concomitant antiepileptic drugs with or without vagus nerve stimulation. During the treatment period (two to five days), oral lacosamide was replaced with intravenous lacosamide, infused at a rate of 10, 15 and 30 minutes.

Intravenous lacosamide was generally well-tolerated and the frequency of adverse events did not increase with more days of exposure or shorter infusion durations. The incidence of adverse events was comparable across all infusion durations (10-, 15- and 30-minute infusions), with headache (5%, 7%, 8%) and dizziness (5%, 6%, 8%) being the most commonly reported. Plasma concentrations were proportional to the actual daily dose given and similar across all infusion duration groups. Intravenous lacosamide was also locally well-tolerated with no serious infusion site reactions. In this study, intravenous lacosamide was administered directly via injection, with no diluent required.

These results support data from an earlier multi-center, double-blind, randomized, inpatient trial that evaluated intravenous lacosamide (200-600 mg/day) as replacement for oral lacosamide in patients with partial onset seizures. In that double-blind trial, intravenous lacosamide showed a similar profile to oral lacosamide when administered as 30- or 60-minute twice daily infusions. The data presented at AAN demonstrated that intravenous lacosamide was also generally well-tolerated at shorter infusion durations.

Intravenous lacosamide was developed as an alternative for patients who temporarily cannot receive oral therapy. Doses of intravenous lacosamide are equivalent to the oral form of the drug and do not require conversion.

About lacosamide: Lacosamide has a dual mode of action and is the first agent of its kind to be clinically studied for the treatment of epilepsy. It selectively enhances slow inactivation of sodium channels and interacts with the neuroplasticity-relevant target-collapsin-response mediator protein-2 (CRMP-2). Lacosamide is also being investigated for its potential effect in reducing diabetic neuropathic pain.

Lacosamide-oral tablet, oral syrup and intravenous formulation-has been filed with the U.S. FDA and the EMEA for use as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy and is currently under review.

Applications for marketing authorization for lacosamide in epilepsy are supported by data from three clinical trials with a total of approximately 1,300 adults with uncontrolled partial onset seizures, despite taking one to three AEDs. In these studies, significantly greater 50% responder rates and reductions in median seizure frequency were seen versus placebo. The most common adverse events of lacosamide (greater than or equal to 10% and greater than placebo) reported in these trials included dizziness, headache, nausea and diplopia.

Further information

Andrea Levin

Public Relations Manager, CNS, UCB

T 770.970.8352

M 404.483.7329

Andrea.levin@ucb-group.com

Sarah Handza

Cooney/Waters Group

T 212.886.2206

M 646.236.1458

Shandza@cooneywaters.com

About UCB

UCB (Euronext: UCB) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta, Georgia. For more information about UCB, visit http://www.ucb-group.com.


'/>"/>
SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
2. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
3. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
4. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
5. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
6. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
7. PG500 Series Presented at the AACR Annual Meeting in San Diego
8. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
11. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... The Cincinnati location of ... (NYSE: DPLO), has been awarded a Top Workplaces 2017 ... Results are based on an employee survey administered by WorkplaceDynamics, ... improvement. The survey measures several aspects of workplace culture, including ... ...
(Date:5/30/2017)... 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading global ... announced that it will be presenting at the 7th annual LD ... Erez Raphael , CEO, of DarioHealth will be giving the ... held on June 6th & 7th, 2017 at the Luxe Sunset ... / micro-cap space. About LD ...
(Date:5/26/2017)... SANTA BARBARA, Calif. , May 25, 2017 /PRNewswire-USNewswire/ ... the United States , Direct Relief is working ... of overdose-reversing Naloxone available at no cost to community ... and other nonprofit providers nationwide. "Pfizer ... expanding access to medicines and ensuring patient safety through ...
Breaking Medicine Technology:
(Date:6/23/2017)... FL (PRWEB) , ... June 23, 2017 , ... ... Pinecrest, Florida. This is MD Now’s 28th facility overall and marks the urgent care ... Highway, located one mile North of The Falls shopping mall. The new clinic offers ...
(Date:6/23/2017)... ... 2017 , ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in ... quarter 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings ... in Denmark in 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance ... to communities in the greater Chicago metropolitan area, is embarking on a charity ... youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is one of ...
(Date:6/23/2017)... Woodlands, TX (PRWEB) , ... June 23, 2017 ... ... families and business owners in the Houston area with access to asset protection ... for a regional charity event aimed at improving the lives of children with ...
(Date:6/22/2017)... ... June 22, 2017 , ... United Benefit Advisors ... Whipple & Company as its newest Partner Firm. Headquartered in Coconut Creek, Florida, ... risk while tailoring optimized benefit packages that strengthen the relationship between employer and ...
Breaking Medicine News(10 mins):